Context: Tapering of long-term opioid therapy (LTOT) increased after publication the 2016 CDC guidelines, followed by anecdotal reports exacerbated pain among tapered patients. However, two systematic reviews limited evidence from multidisciplinary control programs found similar or better ratings tapering versus baseline. Objective: To evaluate association between dose and sub...

OBJECTIVE To compare the real-world, 5-year clinical and cost impact of maintaining treatment with the tumor necrosis factor-α inhibitors (anti-TNFs) adalimumab, etanercept, or infliximab vs dose tapering or withdrawal in rheumatoid arthritis (RA) patients who have achieved remission (defined as a 28-joint count Disease Activity Score [DAS28] < 2.6) or low disease activity (LDA; DAS28 < 3.2). ...

OBJECTIVE To investigate the impact of dose reduction of tumor necrosis factor inhibitor (TNFi) on radiographic progression in ankylosing spondylitis (AS). METHODS One hundred and sixty-five patients treated with etanercept or adalimumab were selected from a consecutive single-center observational cohort based on the availability of radiographs at baseline and after two- and/or four-years of ...

OBJECTIVE In a randomised controlled trial investigating tapering of TNF inhibitors (TNFi) compared with usual care (UC) in rheumatoid arthritis patients, minimal radiographic progression was more frequent in patients who attempted tapering. Possible explanations include higher incidence of flaring, higher mean disease activity or lower TNFi use. METHODS 18 months data from the DRESS study we...